Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

• Status: Recruiting
• Trial end date: 2021-03-15
• Target enrollment: 0
• Participant gender: All

Summary

Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: David Garcia Cinca
• Collaborator: Dr. Josep Mallolas
• Treatments: Lamivudine; Tenofovir

Criteria

Inclusion Criteria:

• Subjects attending emergency room due to potential HIV exposition of either sex:

• Aged 18 years or more.

• Who have been exposed to non-occupational HIV and who meet the prerequisites for the current recommendations to begin prophylaxis post-exposition with three antiretroviral drugs.

• Who after being fully informed, give their written consent to participate in the study and undergo the tests and examinations required.

• Individuals able to do follow up correctly.

Exclusion Criteria:

• Pregnant women or nursing mothers or women trying to conceive during the study period.

• Patients in whom it is known or suspected that the source case has a resistance to one of the drugs from the study treatment regimens.

• Treatment with drugs that are contraindicated in the study or products that are in the investigational phase.

• Allergic reactions or intolerance to the compounds of the study treatment regiments